COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03399448
Recruitment Status : Terminated (Sponsor has terminated trial to pursue other targets.)
First Posted : January 16, 2018
Last Update Posted : October 12, 2020
Parker Institute for Cancer Immunotherapy
Tmunity Therapeutics
Information provided by (Responsible Party):
University of Pennsylvania